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OBJECTIVE—Adipose inﬂammation plays a central role in
obesity-related metabolic and cardiovascular complications.
However, few human adipose-secreted proteins are known to
mediate these processes. We hypothesized that microarray
mRNA proﬁling of human adipose during evoked inﬂammation
could identify novel adipocytokines.
RESEARCH DESIGN AND METHODS—Healthy human vol-
unteers (n  14) were treated with intravenous endotoxin (3
ng/kg lipopolysaccharide [LPS]) and underwent subcutaneous
adipose biopsies before and after LPS. On Affymetrix U133Plus
2.0 arrays, adipose mRNAs modulated 1.5-fold (with P 
0.00001) were selected. SignalP 3.0 and SecretomeP 2.0 identiﬁed
genes predicted to encode secreted proteins. Of these, 86 candi-
dates were chosen for validation in adipose from an independent
human endotoxemia protocol (N  7, with 0.6 ng/kg LPS) and for
exploration of cellular origin in primary human adipocytes and
macrophages in vitro.
RESULTS—Microarray identiﬁed 776 adipose genes modulated
by LPS; 298 were predicted to be secreted. Of detectable priori-
tized genes, 82 of 85 (96% [95% CI 90–99]) were upregulated (fold
changes 1.0) during the lower-dose (LPS 0.6 ng/kg) validation
study and 51 of 85 (59% [49–70]) were induced greater than
1.5-fold. Treatment of primary adipocytes with LPS and macro-
phage polarization to M1 proinﬂammatory phenotype increased
expression by 1.5-fold for 58 and 73% of detectable genes,
respectively.
CONCLUSIONS—We demonstrate that evoked inﬂammation of
human adipose in vivo modulated expression of multiple genes
likely secreted by adipocytes and monocytes. These included
established adipocytokines and chemokines implicated in re-
cruitment and activation of lymphocytes, adhesion molecules,
antioxidants, and several novel genes with unknown function.
Such candidates may represent biomarkers and therapeutic
targets for obesity-related complications. Diabetes 58:2211–
2219, 2009
A
ctivation of innate and adaptive immunity is a
crucial link between adiposity and its metabolic
complications (1–4). In rodents, modulation of
toll-like receptor-4 (5), tumor necrosis factor
(TNF) receptors (6), chemokines, and downstream ki-
nases (7) attenuate diet-induced obesity and insulin resis-
tance. Further, cross talk between immune cells and
adipocytes promotes an inﬂammatory, insulin-resistant
state in obesity. A key initiating event in adipose inﬂamma-
tion is recruitment of T-lymphocytes (8,9) and monocyte/
macrophages (10,11) with elaboration of inﬂammatory
adipocytokines that modulate metabolic signaling (12–15).
Despite experimental evidence in rodent models, most evi-
dence supporting these concepts in humans derives from
observational and correlative studies (16–18). Indeed, vali-
dated adipokines that mediate, or serve as biomarkers for,
complications of human adiposity remain limited.
Expression of inﬂammatory, insulin-signaling, and lipid
genes are perturbed in adipose of obese humans (19–21).
Recently, the in vitro secretome of subcutaneous and
visceral primary human adipocytes was described and
includes many unexplored proteins modulated during ad-
ipogenesis (1,22). Remarkably, less than half of genes
found in the human subcutaneous adipocyte secretome
were previously found in the murine 3T3-L1 preadipocyte
secretome (22), underscoring the importance of studies in
human tissue.
Experimental human endotoxemia can provide unique
insights into the relationship of inﬂammation to metabolic
disturbance in man (23,24). Others and we have shown
that endotoxemia induces acute metabolic, lipoprotein,
and oxidant responses that resemble the chronic changes
in insulin resistance and metabolic syndrome (25,26).
Notably, endotoxemia induces adipose inﬂammation (27)
with activation of several adipose inﬂammatory cascades,
including cytokines, chemokines, and suppressor of cyto-
kine signaling (SOCS) molecules (26) that attenuate insu-
lin signaling and are implicated in obesity and type 2
diabetes (28).
We applied microarray mRNA proﬁling of human adi-
pose during endotoxemia to identify novel inﬂammation-
induced adipose genes. We focused on genes predicted to
be secreted and validated our ﬁndings in vivo through
independent experiments of low-grade human inﬂamma-
tion. Finally, we identiﬁed in vitro the likely human
adipose cellular source of these top candidates.
RESEARCH DESIGN AND METHODS
An overview of our design is provided in Fig. 1. All clinical studies were
performed with approval of University of Pennsylvania Institutional Review
Board after written informed consent from all subjects.
From the
1Division of Pediatric Endocrinology, Children’s Hospital of Phila-
delphia, Philadelphia, Pennsylvania; the
2Center for Clinical Epidemiology
and Biostatistics, Philadelphia, Pennsylvania; the
3Cardiovascular Institute,
Philadelphia, Pennsylvania; the
4Institute for Diabetes Obesity and Metab-
olism, Philadelphia, Pennsylvania; and the
5Department of Genetics, Uni-
versity of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Corresponding author: Muredach P. Reilly, muredach@mail.med.upenn.edu.
Received 21 February 2009 and accepted 16 June 2009.
Published ahead of print at http://diabetes.diabetesjournals.org on 6 July 2009.
DOI: 10.2337/db09-0256.
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
diabetes.diabetesjournals.org DIABETES, VOL. 58, OCTOBER 2009 2211Discovery human endotoxemia protocol. As previously described (26),
healthy volunteers, aged 18–40 years, with BMI 18–30 kg/m
2 were recruited
from the Delaware Valley. Exclusions included past medical history including
inﬂammatory diseases, medication or supplement use, or pregnancy. Partici-
pants underwent three Clinical and Translational Research Center visits: visit
one for screening; visit two for dietary run-in; and visit three for inpatient stay
comprising an acclimatization phase and a postlipopolysaccharide (post-LPS)
study phase. Serial whole blood samples were collected before and 2, 4, 6, 8,
12, 16, and 24 h after intravenous bolus of 3 ng/kg U.S. standard reference
endotoxin (LPS; lot No. CC-RE-LOT-1  2; Clinical Center, National Institutes
of Health, Bethesda, MD). Serial subcutaneous adipose samples were col-
lected by core needle aspiration througha4m mgluteal incision from distinct
sites, 30 min before and 4, 12, and 24 h after LPS; samples were treated with
RNA Later and stored at 70°C. This report focuses on the subset that
underwent microarray mRNA proﬁling of adipose (N  14).
Microarray. Adipose tissue RNA was extracted using RNeasy Lipid Tissue
Mini kit (Qiagen, Valencia, CA) and underwent extensive quality control (QC)
(including spectrometry, picogreen quantitation, and electrophoresis for RNA
quality) before ﬁrst-strand cDNA synthesis (100 ng), cRNA synthesis, and
hybridization to Affymetrix GeneChip Human Genome U133Plus 2.0 arrays
(Santa Clara, CA) in the Penn Microarray Facility (www.me.upenn.edu/
microarr/). Microarrays were washed and then stained with ampliﬁed ﬂuores-
cence markers, and signals were collected on a confocal scanner at 3 m
resolution (excitation at 570 nm). Affymetrix Microarray Suite 5.0 was used to
quantitate expression levels of average signal from two sequential scans.
Array signal intensities passed a two-stage QC process including affyQCReport
package. All arrays had similar background values and distributions of
intensity.
Adipose microarray statistical and informatic methods
Identiﬁcation of candidate LPS-modulated genes. Arrays were normal-
ized, adjusted for background signal using robust multiarray analysis (29), and
ﬁltered by removing probesets with little evidence of expression using the
PM/MM probes (63) or expression levels consistently less than threefold
background. For the remaining 13,646 genes, mixed effects models using
shrinkage estimates of the variance components were ﬁt, with the goal of
identifying genes with highly signiﬁcant fold changes in expression between
baseline and each time point (4, 12, and 24 h). Genes were selected for further
study if the permutation-based P value for the null hypothesis test of a fold
change of unity at any time point was less than 1  10
5 (30). Permutation-
based false discovery rates were assessed at each time point (31). To increase
the chance of identifying genes with detectable changes at the protein level,
we required a minimum cutoff of at least 1.5-fold change in intensities per
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FIG. 1. Overview of study design and results. The discovery study utilized microarray analysis of human adipose tissue isolated during in vivo
endotoxemia (3 ng/kg) to identify genes modulated by inﬂammation (n  776). Bioinformatics tools (SignalP 3.0 or SecretomeP 2.0 score >0.7)
established which of these were likely to encode secreted proteins (n  298). This list was prioritized to create a subset of genes (n  86) based
upon 1) novelty, 2) degree of induction, 3) sustained upregulation, 4) prior publication as secreted proteins in vitro or in vivo, 5) evidence for
functional roles in inﬂammation, insulin signaling, or adipose biology, and 6) known association with diseases of interest. The validation study
involved RT-PCR analysis of these 86 genes in human adipose isolated during in vivo endotoxemia (0.6 ng/kg) to conﬁrm microarray ﬁndings and
to identify genes modulated during lower-grade, more physiologic inﬂammation. Cell studies in primary human adipocytes after treatment with
LPS and macrophages after polarization to inﬂammatory (M1) phenotype were also performed to determine likely cellular origin of these 86
genes.
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run under R 2.6 (R Foundation for Statistical Computing, Vienna, Austria) with
libraries including affy, maanova, and panp.
Secreted protein identiﬁcation. We interrogated in silico our candidate
LPS-modulated genes using the validated protein informatic software SignalP
3.0 (http://www.cbs.dtu.dk/services/SignalP/) (32,33) and SecretomeP 2.0
(http://www.cbs.dtu.dk/services/SecretomeP/) (34) to identify the subset of
human genes with highest probability of encoding either signal peptides
(SignalP) or protein sequences predictive of nonclassic secretion (Secre-
tomeP). For SignalP, we used a cutoff D-score of 0.7 as the score above which
frequency of containing a signal peptide is greatly increased in known
eukaryotic proteins (32). A SecretomeP cutoff of 0.7 was chosen as the cutoff
above which Bendsten et al. (34) demonstrated that all positive training
examples and no negative training examples were classiﬁed as nonclassically
secreted. Genes encoding sequences that met the cutoff value for either
classic or nonclassic secretion comprise our preliminary candidate “human
adipose tissue inﬂammatory secretome.”
Prioritization for validation. For initial prioritization, we focused on
upregulated genes as being more likely to have detectable and increased
protein levels in adiposity-related disease. Thus, candidate inﬂammatory,
adipose-secreted proteins were prioritized as follows: 1) novelty genes with
unknown functions, 2) threefold upregulation at any time point, 3) 1.5-fold
upregulation at two or more time points, 4) prior publication as secreted
proteins in vitro or in vivo, 5) evidence for functional roles in inﬂammation,
insulin signaling, or adipose biology, and 6) known association with diabetes,
obesity, metabolic syndrome, or cardiovascular disease. Genes that did not
meet any of the criteria were not studied further. This resulted in a list of 86
candidates (including positive controls interleukin [IL]-6, TNF, and monocyte
chemotactic protein [MCP]-1) that were selected for validation and identiﬁ-
cation of adipose tissue cell of origin.
Functional classiﬁcation. Prioritized genes were uploaded to DAVID
(Database for Annotation, Visualization, and Integrated Discovery) Bioinfor-
matics Resource and the Gene Functional Classiﬁcation tool was utilized to
generate clusters of related and overrepresented genes (35,36). The enrich-
ment score (geometric mean of log P values) is presented.
Validation human endotoxemia protocol. Healthy volunteers (n  10)
were recruited from the same population as Discovery Study, using similar
criteria. Eligible participants underwent dietary counseling and were admitted
for inpatient stay including acclimatization and post-LPS phases. Serial whole
blood (at 0, 2, 4, 6, 12, 16, and 24 h) and subcutaneous gluteal adipose tissue
samples (at 0, 4, 12, and 24 h) were collected before and after intravenous
infusion of 0.6 ng/kg endotoxin and processed as above. We focused on the subset
(n  7) in whom adipose tissue samples were assayed by quantitative PCR.
Cell studies
Primary human adipocyte studies. Fresh human adipose tissue obtained
from abdominal surgery specimens via the Penn Human Adipose Resource
was the source of primary human adipocytes. Brieﬂy, the specimen was
digested with collagenase (Roche Applied Science, Indianapolis, IN), ﬁltered,
and centrifuged, and the cellular layer was resuspended in OF medium
(DMEM/F12 plus penicillin/streptomycin, biotin [4 mg/l] and pantothenate [8
mg/l]) with 20% FBS and plated at 30,000 cells/cm
2. Once conﬂuent, cells were
differentiated in serum-free differentiation medium (OF media, insulin [20
nmol/l], hydrocortisone [1 mol/l], dexamethasone [250 nmol/l], human
transferrin [10 mg/l], T3 [0.2 nmol/l], isobutylmethylxanthine [500 mol/l], and
peroxisome proliferator–activated receptor- agonist GW347845 [2 mol/l]
[gift from GlaxoSmithKline, King of Prussia, PA]) until 80% mature (7–10
days). Cells were washed and treated 	LPS 100 ng/ml in DMEM/F12 with 0.1%
FBS plus penicillin/streptomycin for 2, 4, 12, and 24 h for two independent
experiments, in triplicate. Unless noted, reagents were purchased from
Sigma-Aldrich (St. Louis, MO).
Primary human macrophage studies. Human monocytes (peripheral
blood mononuclear cells, 95% expression of CD14 and HLA-DR) were
isolated from donor blood after apheresis and elutriation in the Penn Center
for AIDS Research. As described (37), cells were plated at 3  10
5 cells/cm
2
and cultured in RPMI with 20% FBS and penicillin/streptomycin then supple-
mented with 100 ng/ml MCSF (Sigma, St. Louis, MO) to promote differentia-
tion to macrophages over 7 days. In two independent experiments, each in
triplicate, macrophages were washed and treated for 16 h with RPMI  5%
FBS alone, 100 ng/ml LPS and 20 ng/ml Interferon Gamma (R&D Systems,
Minneapolis, MN) for differentiation to the M1 phenotype, or 20 ng/ml
recombinant human IL4 (R&D Systems) for differentiation to the M2 pheno-
type (38).
General laboratory methods
RNA extraction, cDNA synthesis, and quantitative PCR. RNA was
isolated from adipose tissue, adipocytes, and macrophages using Trizol
reagent (Invitrogen, Carlsbad, CA) and was reverse transcribed (500 ng) to
cDNA (High Capacity cDNA Archive Kit; ABI, Foster City, CA). Expression of
genes was determined by real-time PCR (ABI7900 system) using TaqMan
Universal PCR MasterMix primers and probes. To control for between-sample
differences, mRNA levels were normalized to 
-actin for each sample by
subtracting the Ct for 
-actin from the Ct for gene of interest, producing a Ct
value. The Ct for each post-treatment sample was compared with the mean
Ct for all pretreatment samples using the relative quantitation 2
Ct method
to determine fold change from baseline (39).
Metabolic and inﬂammatory markers. As previously described (26),
plasma levels of TNF-, IL-6 (Linco Multiplex ELISAs on Luminex IS100;
Austin, TX), and C-reactive protein (high-sensitivity Latex turbidimetric
immunoassay; Wako, Osaka, Japan) were measured in duplicate per manu-
facturers’ guidelines. Intra- and interassay coefﬁcients of variation for TNF
ELISA were 8.66 and 20.4%, respectively, and for IL-6, 8.7 and 10.9%,
respectively. Plasma lipids and glucose were measured enzymatically on Hitachi
912 automated chemistry (Wako Diagnostics, Richmond, VA) (26). Subject data
are reported as means 	 SD for continuous variables and as proportions for
categorical variables. Effects of endotoxemia on clinical parameters were tested
by mixed-effects modeling or repeated-measures ANOVA (26).
Statistical analysis of quantitative PCR data. For validation, study
adipose tissue fold changes at each time point were estimated using the
method of generalized estimating equations to account for within-subject
correlations. For adipocytes and macrophages, analysis of mRNA fold change
utilized geometric means of the independent replicated samples. For the time
point with peak fold change, the means and 95% CIs are reported for all studies.
Correlation analyses between studies were performed by Spearman’s rank
correlation of the log10 peak fold change. The proportions of upregulated genes
for validation, adipocyte, and macrophage studies were reported, and their 95%
exact binomial CIs were calculated using Clopper and Pearson (40). Analyses
were performed using the R 2.6 and Stata 10 (StataCorp, College Station, TX).
RESULTS
Baseline characteristics of participants and clinical
responses to endotoxemia. Participants in the discovery
and validation studies had similar baseline characteristics
with normal blood pressure, plasma lipoproteins, and BMI,
although the validation study enrolled more female partic-
ipants (Table 1). In the discovery study, as reported (26),
there was a transient clinical and biochemical inﬂamma-
tory response to LPS 3 ng/kg, whereas the lower LPS dose
of 0.6 ng/kg in the validation study produced a subclinical
response with modest increases in plasma cytokines but
no signiﬁcant symptoms or fever (Table 2).
Endotoxemia modulates expression of many human
adipose tissue genes. We identiﬁed 696 genes at 4 h, 130
genes at 12 h, and 24 genes at 24 h that met criterion for
TABLE 1
Baseline characteristics of the discovery and validation study
samples
Discovery study
3 ng/kg
endotoxin
(n  14)
Validation study
0.6 ng/kg
endotoxin
(n  7)
Age (years) 25.0 	 6.5 24.4 	 3.1
Female sex, n (%) 4 (28%) 5 (71%)
Race
White (%) 12 (86%) 6 (86%)
African American (%) 2 (14%) 1 (14%)
Systolic blood pressure
(mg Hg) 121 	 9 115 	 7.9
BMI (kg/m
2) 24.0 	 4.0 24.4 	 2.6
Fasting glucose (mmol/l) 4.68 	 0.28 3.89 	 0.77
Total cholesterol (mmol/l) 4.53 	 0.52 4.65 	 0.60
LDL cholesterol (mmol/l) 2.46 	 0.67 2.21 	 0.56
HDL cholesterol (mmol/l)
Men 1.33 	 0.26 1.24 	 0.05
Women 1.69 	 0.34 1.81 	 0.19
Triglycerides (mmol/l) 0.86 	 0.39 1.0 	 0.3
Data are means 	 SD unless otherwise indicated.
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points were 3  10
5,4 10
4, and 0.001, respectively,
suggesting strong evidence of differential expression
among these genes. Many genes were modulated at mul-
tiple time points, resulting in 776 unique genes modulated
at any time point (696 at 4 h, 68 additional at 12 h, and 12
additional at 24 h). Approximately half the genes were
upregulated (fold change 1.5), the remaining were down-
regulated (Table 3).
A subset of modulated adipose tissue genes is pre-
dicted to encode secreted proteins. Based on the
SignalP 3.0 and SecretomeP 2.0 analysis, a total of 266
genes at 4 h, 72 at 12 h, and 15 at 24 h were predicted to
encode secreted proteins (Table 3). This corresponds to
298 unique genes and represents 38% of all modulated
genes, suggesting an over-representation of secreted pro-
teins relative to the entire Affymetrix U133Plus 2.0 array
(
24%) and the human genome (15–20%). The majority of
these (75%) were predicted to be classically secreted.
More were upregulated (63% at 4 h and 12 h, 54% at 24 h)
than downregulated.
For the current report, only upregulated genes predicted
to encode secreted proteins were chosen for further
validation (n  86). These inﬂammatory, human adipose
tissue–secreted factors included cytokines (e.g., IL6,
TNF), chemokines (e.g., CXCL9, CCL4), growth factors
(e.g., BMP-2), acute-phase reactants (e.g., PTX3, HP),
adhesion molecules (e.g., ICAM1, VCAM), cell surface
markers (e.g., CD14, CD274), antioxidants (e.g., metallo-
thioneins), and novel genes with unknown functions (e.g.,
C19orf59, KIAA0247). In addition, several prioritized genes
were identiﬁed that have been implicated in inﬂammatory
processes in human or animal models but not described in
adipose function (e.g., CEACAM, ISG15, CX3CL1). The
heatmap in supplemental Fig. 1, available in an online
appendix at http://diabetes.diabetesjournals.org/content/
early/2009/06/23/db09-0256/suppl/DC1 depicts fold changes
(ranked from highest to lowest fold change) in the discov-
ery study adipose, as determined by microarray. Greatest
mRNA modulation occurred at 4 h, but some genes had
later induction or sustained modulation over time.
The majority of prioritized genes fall into six func-
tional categories deﬁned by DAVID. Figure 2 depicts the
overrepresented categories that include cell adhesion,
chemokine and cytokine, acute-phase response, T-cell
activation, metal binding, and lipid metabolism. Re-
markably, 28 genes including many unknowns remained
uncategorized. Supplemental Table 1 (available in an
online appendix) gives the full lists of genes in each
category.
Inﬂammatory modulation of many prioritized genes
replicates in human adipose tissue samples during an
independent validation endotoxemia study. We repli-
cated endotoxemia-induced adipose tissue genes in an
TABLE 2
Clinical and inﬂammatory responses to endotoxemia
Discovery study (n  14) Validation study (n  7)
Pre-LPS Post-LPS
Time of
peak Pre-LPS Post-LPS
Time of
peak
TNF (pg/ml) 3.0 	 1.1 507 	 251* 2 h 1.0 	 0.6 22 	 13† 2 h
IL-6 (pg/ml) 3.2 	 17.1 1,607 	 650* 2 h 1.7 	 1.8 107 	 31* 2 h
Heart rate (bpm) 76 	 11 107 	 13.6* 4 h 64 	 11 80 	 15‡ 4 h
Temperature (
C) 36.5 	 0.3 37.8 	 0.9* 4 h 36.4 	 0.4 36.7 	 0.4 4 h
White blood cell count 6.5 	 1.2 13.8 	 3.2* 12 h 6.1 	 1.4 8.4 	 1.9‡ 4 h
High-sensitivity C-reactive protein (mg/l) 0.49 	 0.21 42.4 	 8.4† 24 h 1.5 	 1.5 16.7 	 7.6† 24 h
Data are means 	 SD unless otherwise indicated. For each study, within-subject pre- vs. post-LPS comparisons are reported. *P  0.0001,
†P  0.005, ‡P  0.05.
TABLE 3
Summary of data for modulated genes and secreted proteins in
adipose during human endotoxemia
Time post-LPS
Modulated
genes Secreted
Classically
secreted
4h
Total number 696 266 198 (75)
Upregulated 414 (61) 168 (63)
12 h
Total number 130 72 57 (80)
Upregulated 75 (58) 45 (64)
24 h
Total number 24 15 11 (72)
Upregulated 11 (46) 8 (46)
Data are n or n (%). Number of genes up- or downregulated 1.5 fold
are shown.
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FIG. 2. Database for DAVID functional categories with enrichment
scores. Numbers of genes in each category are listed above each bar.
The majority of genes are categorized into inﬂammatory pathways but
some cluster into lipid and metal-binding categories. Many genes (28 of
86), often with unknown functions, did not classify into any known
categories.
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kg). This dose resulted in modest cytokine induction
without clinically signiﬁcant responses and therefore may
more closely reﬂect the modest inﬂammation observed in
human obesity. Of the 86 prioritized genes, 85 (98% [95% CI
94–100]) were conﬁrmed to be expressed (Ct value 37).
During 0.6 ng/kg endotoxemia, 82 of 85 (96% [90–99]) were
increased (fold changes 1.0) and 51 of 85 (60% [49–70])
were upregulated by greater than 1.5-fold. The heatmap in
supplemental Fig. 2 depicts mRNA expression changes
over time. Compared with the discovery study, the lower-
dose LPS validation study induced a more modest but
similar pattern of expression (Fig. 3A). Remarkably, there
was a relatively high correlation (r  0.64, P  0.0001) of
FIG. 3. Comparison between endotoxin-induced adipose mRNA fold change in
discovery versus validation study. A: Heatmap depicting direct comparison of
4 h log10 expression changes of 86 high-priority genes in discovery study versus
validation study, ranked in order of log10 fold change in discovery study. The
National Center for Biotechnology Information gene identiﬁcation names are
listed on the right. Time 0 values are set to one (log10 changes  0). Color
coding: 0 is set to orange as seen at baseline, yellow indicates upregulation, red
indicates downregulation. B: Correlation (Spearman) between log10 peak fold
change of 85 detectable genes in discovery versus validation study. r  0.64;
P < 0.0001.
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dation studies (Fig. 3B).
The majority of the putative adipose tissue inﬂam-
matory secretome is expressed in human adipocytes
and induced by LPS in vitro. Analysis of primary human
adipocytes revealed that 77 of 86 (90%) prioritized genes
had detectable expression (Ct value 37) in resting adi-
pocytes, 68 of 77 (88% [95% CI 79–94]) were increased
(1.0-fold), and 50 of 77 (65% [53–75]) were upregulated
by greater than 1.5-fold after 100 ng/ml LPS. There was a
remarkable correlation of peak mRNA fold change be-
tween discovery human adipose and adipocytes (Fig. 4A)
as well as between validation adipose and adipocytes (Fig.
4B), suggesting that adipocytes are a major source of
inﬂammatory modulated genes in human adipose tissue in
vivo.
Many candidate genes are expressed in human mac-
rophages and upregulated during polarization to the
M1-phenotype. Next, expression was tested in classically
activated proinﬂammatory (M1) and alternatively acti-
vated anti-inﬂammatory (M2) macrophages (41,42) relative
to undifferentiated macrophages. In resting macrophages,
72 of 86 mRNAs (84%) were detectable (Ct 37) whereas
66 of 72 (92% [95% CI 83–97]) were increased (1.0-fold)
and 63 of 72 (88% [78–94]) were upregulated by 1.5-fold
during polarization to the M1 phenotype, supporting their
potential role in inﬂammatory macrophage signaling in
human adipose tissue. In contrast, genes upregulated in
adipose tissue tended to be unchanged or downregulated
in M2 macrophages; only 22 of 72 (31% [21–43]) were
increased 1.0-fold and 14 of 72 (20% [11–31]) were
upregulated 1.5-fold.
A summary of ﬁndings in the discovery and validation
studies as well as in primary human adipocytes and human
macrophages is presented in supplementary Table 2, avail-
able in an online appendix. Overall, of the 51 genes
conﬁrmed to be upregulated 1.5-fold in human adipose
tissue in our validation study, the majority (46 of 51, 90%)
was induced by LPS in adipocytes and/or M1 macrophages
(Table 4).
DISCUSSION
This mRNA microarray analysis of human adipose tissue
during experimental endotoxemia is the ﬁrst attempt to
identify novel adipocytokines using an in vivo evoked
adipose inﬂammatory model. Our strategy identiﬁed genes
encoding established adipokines implicated in obesity-
related insulin resistance as well as emerging adipose
tissue–secreted factors (1) and multiple secreted proteins
with unknown adipose functions. These experimental hu-
man studies are internally consistent, provide independent
validation, and deﬁne the likely cellular origin. Such
candidates may represent new biomarkers and therapeutic
targets for the treatment of obesity-related complications.
Microarray analysis of gene expression is established
for discovery of disease-related genes (43). Indeed, mRNA
proﬁling of adipose has identiﬁed novel genes involved in
obesity and type 2 diabetes (44). Several reports identiﬁed
genes involved in inﬂammation, insulin signaling, and lipid
metabolism as differentially expressed in adipose tissue of
obese humans (19–21). We also identiﬁed many of these
genes suggesting that our model may be useful in human
adipokine discovery. For example, 9 of 89 genes differen-
tially expressed in omental adipose of obese subjects
(20) were also upregulated in our study (ADRB2, IFIT2,
IL10RA, IL6, ISG20, JAK2, LDL4, MAP3K4, and NGFR). In
adipocytes cultured ex vivo from subcutaneous adipose of
obese versus nonobese Pima Indians, 38 upregulated
genes were also increased in our study (21), including 13
likely secreted proteins that we prioritized for validation
(APOL1, APOL3, CCL2, CCL4, CD14, CXCL1, CXCL2,
CXCL3, ICAM2, IER3, MT2A, SERPINE1, and TNFRSF1A).
The dose of LPS (3 ng/kg) used in the discovery study
induced an acute and more marked inﬂammatory state
than that found in obesity. This superphysiologic acti-
vation of innate immunity allowed us to identify in vivo a
broad range of adipose inﬂammatory genes, with the
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FIG. 4. Comparison between endotoxin-induced mRNA fold change in human adipose versus primary adipocytes. A: Spearman correlation between
log10 peak fold change of 77 detectable genes in primary human adipocytes (after 100 ng/ml LPS) and human adipose in discovery study (3 ng/kg
endotoxin). r  0.49; P < 0.0001. B: Correlation between log10 peak fold change of 77 detectable genes in primary human adipocytes (after 100
ng/ml LPS) and human adipose in validation study (0.6 ng/kg endotoxin). r  0.42; P < 0.0001.
TABLE 4
Induction of validated adipose genes (n  51) by LPS in human
adipocytes and during polarization to M1 macrophages
Up in adipocytes Not up in adipocytes
Up in M1 32 (63%) 9 (18%)
Macrophages CCL8, CXCL10, MT2A CXCL9, IL2RA, SLAMF1
Not up in M1 5 (10%) 5 (10%)
Macrophages TNFSF14, ICOSLG,
ANGPT2
LCN6, DIO3, CEACAM1
Data are n (%). Number of genes upregulated 1.5 fold in respective
cell-type are shown, along with examples of genes in each category.
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that in human adiposity. To explore our ﬁndings in a
setting more relevant to the low-grade inﬂammation in
central obesity, we validated adipose tissue upregulation
in an independent human study of very-low-dose endotox-
emia (0.6 ng/kg) that results in modest cytokine induction
without signiﬁcant clinical inﬂammatory responses. Nota-
bly, the majority of adipose tissue–upregulated genes
identiﬁed in the discovery study were also induced in the
validation study, suggesting that they may be modulated
during the more modest adipose inﬂammation of obesity.
Our in silico–predicted adipose inﬂammatory secretome
is remarkable because it included 1) many established
adipocytokines including TNF, IL-6, MCP-1, plasminogen
activator inhibitor (PAI)-1, and selectin E; 2) secreted
inﬂammatory molecules with known immune functions
but no known role in adipose or metabolic signaling (e.g.,
CX3CL1, ISG15, and EBI3); 3) a number of proteins
recently identiﬁed in the human visceral adipose secre-
tome (1) (e.g., CSF-1, PAI-1, ADAMSTS, and PTX3); and 4)
multiple genes encoding secreted proteins without known
functions. Functional classiﬁcation of the 86 genes re-
vealed several expected inﬂammatory categories including
acute-phase response, chemokines and cytokines, as well
as cell adhesion molecules. The overrepresentation of
T-cell–activating genes is of particular interest, given the
recent implication of T-cell recruitment in obesity-related
adipose tissue inﬂammation and insulin resistance (2,8,45).
An inﬂammatory impact on adipocyte metabolic and redox
activities is suggested by excess representation of lipid
and metal-binding gene categories. Notably, 28 genes,
many with completely unknown functions, remained un-
categorized, highlighting the potential for this model to
provide novel insights into human adipose biology.
As macrophage inﬁltration is a key event in adipose
tissue inﬂammation and insulin resistance (10,11), we
expected that the evoked inﬂammatory state would induce
factors involved in recruitment and differentiation of
monocytes. Chemokines such as MCP1, CSF1, CXCL3, and
CX3CL1 were upregulated at early time points. Macro-
phage cell markers, such as CD14 and CD64, and macroph-
age-secreted proteins such as MIP-1 (CCL3), IL8, and
IL18BP were also induced by LPS. In fact, many of the
overexpressed genes are known to be macrophage se-
creted, and our validation studies in human M1 macro-
phages conﬁrmed that 
75% of genes induced in adipose
tissue by LPS were also upregulated during in vitro polar-
ization to inﬂammatory macrophages.
Macrophages are polarized from a resting state to “clas-
sically activated” (M1) or “alternatively activated” (M2)
phenotypes with proinﬂammatory or anti-inﬂammatory
activities, respectively (41,42). In mouse models, obesity
induces a phenotypic switch in adipose tissue macro-
phages (ATMs) from a predominantly M2 phenotype that
protects against insulin resistance to an M1 inﬂammatory
state that confers sensitivity to TNF-induced insulin
resistance (46). In humans, ATMs possess a complex
phenotype with some M2 markers but M1-like proinﬂam-
matory cytokine production (47). Of note, our predicted
adipose inﬂammatory secretome contained 22 genes found
to be upregulated in the M1 phenotype compared with
resting macrophages (48), and our human macrophage
studies conﬁrmed M1-macrophages as a potential source
of many inﬂammatory molecules.
T-cell recruitment to adipose tissue has been recently
identiﬁed in obesity-induced adipose inﬂammation. In fact,
some ﬁndings suggest T-cells are found in adipose and can
induce insulin resistance before macrophage recruitment
(2,8,45). These inﬂammatory T-cells secrete cytokines/
chemokines that switch resident ATMs to the M1 pheno-
type while recruiting additional circulating monocytes.
Several potent T-cell chemokines, including CCL4, CXCL9,
CXCL10, CXCL11, and IL15, were highly induced by endo-
toxin. Additionally, overexpression of T-cell–induced genes
(ISGs, ICOSLG, and IRFs) was detected, suggesting in-
creased T-cell activity.
We conﬁrmed in vitro that both human adipocytes and
M1-proinﬂammatory macrophages are likely cellular
sources for the vast majority of our adipose inﬂammatory
secretome. By focusing on these cells, we have excluded
other adipose components (e.g., stromal cells). Of genes
validated as upregulated in human adipose inﬂammation,
however, only ﬁve were not induced by LPS in either
adipocytes or macrophages. This ﬁnding suggests these
cells are the principle source of inﬂammatory modulation.
Our study used subcutaneous gluteal adipose tissue
from healthy humans. Although visceral adipose tissue is
commonly held to be more active in obesity-related inﬂam-
mation, it appears that the evoked inﬂammatory response
in subcutaneous adipose tissue approaches a similar phe-
notype. Many genes previously found to be overexpressed
in visceral adipose were upregulated in subcutaneous
adipose during in vivo endotoxemia. Several of the pro-
teins identiﬁed in a recently published human visceral
adipose secretome (1) were also upregulated in our dis-
covery microarray (NETO1, RBP, PAI-1, THSD1, CD14,
PTX3, LUM, and SPON2). These ﬁndings support our use
of subcutaneous adipose tissue. In fact, a recent analysis
revealed that both subcutaneous and visceral depots dis-
played a proinﬂammatory phenotype with obesity (49).
We acknowledge that our acute evoked inﬂammatory
model does not reproduce the chronic low-grade changes
in diet and obesity-related adipose inﬂammation. How-
ever, our prioritized inﬂammatory adipose molecules are
cogent biomarkers for obesity-related diseases. First, the
transient inﬂammatory and metabolic responses to endo-
toxemia resemble those observed in insulin resistance and
metabolic syndrome (23,24). Second, rodent models have
proven that adipose inﬂammatory pathways play impor-
tant roles in diet and obesity-related metabolic distur-
bance (5–7). Finally, mRNA microarray and secretome
proﬁling of human adipose tissue and adipocytes identify
inﬂammatory pathways in obesity similar to those classi-
cally activated by endotoxin (1,20,21). Additional studies
are required to conﬁrm changes at the protein level, and
mechanistic studies are required to determine whether our
prioritized genes are truly involved in adipose metabolic
functions.
In conclusion, human endotoxemia induces adipose
inﬂammation and upregulates many adipose genes and
proteins implicated in the complications of obesity. Microar-
ray analysis of human adipose tissue during endotoxemia
also identiﬁed novel genes that may serve as potential
biomarkers of and therapeutic targets for obesity-related
diseases.
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